Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Microsc Res Tech ; 86(7): 823-833, 2023 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-37232066

RESUMO

Green synthesis of nanoparticles is an emerging field due to it's biosafety and promising results. Biological systems due to their biodiversity are employed in different production processes. In this study Spirulina platensis mediated silver nanoparticles (S-AgNPs) production was done. The Uv spectra, FTIR and SEM analysis was performed for the characterization of biosynthesized S-AgNPs. The biocompatibility evaluation of S-AgNPs was done through hemolysis analysis. S-AgNPs were also evaluated for anticoagulant and thrombolytic potential. In addition to the medical applications of S-AgNPs, silver nanoparticles have been known to show potential industrial applications among which one application is the utilization of silver nanoparticles in the degradation of toxic industrial dyes. Therefore, degradation assay of Eosin Y and Methylene Blue dyes was estimated. The SEM analysis of S-AgNPs showed the particle size of 50-65 nm, whereas the biocompatibility analysis showed that these S-AgNPs are biocompatible at ≤400 µM concentration. The S-AgNPs showed good anticoagulant potential and thrombolytic potential and were able to degrade 44% of the thrombus. The S-AgNPs significantly degraded 76% of Eosin Y within 30 min, whereas Methylene Blue was 80% degraded within 20 min (P-value ≤ .001). To the best of our knowledge, the dye degradation of Eosin Y, thrombolytic activity and anticoagulant activity of S-AgNPs produced from the biomass of Spirulina platensis has been reported for the first time. In the current study, we conclude that our biosynthesized S-AgNPs showed promising medical and industrial applications and these nanoparticles can be further evaluated and upscaled for large scale applications.


Assuntos
Corantes , Nanopartículas Metálicas , Prata/farmacologia , Amarelo de Eosina-(YS) , Azul de Metileno , Anticoagulantes , Extratos Vegetais , Antibacterianos
2.
Life Sci ; 291: 120282, 2022 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-34990649

RESUMO

AIMS: AGEs augment inflammatory responses by activating inflammatory cascade in monocytes, and hence lead to vascular dysfunction. The current study aims to study a plausible role and mechanism of a new library of indole-tethered 1,2,3-triazoles 2-13 in AGEs-induced inflammation. MATERIAL AND METHODS: Initially, the analogs 2-13 were synthesized by cycloaddition reaction between prop-2-yn-1-yl-2-(1H-indol-3-yl) acetate (1) and azidoacetophenone (1a). In vitro glycation, and metabolic assays were employed to investigate antiglycation and cytotoxicity activities of new indole-triazoles. DCFH-DA, immunostaining, Western blotting, and ELISA techniques were used to study the reactive oxygen species (ROS), and pro-inflammatory mediators levels. KEY FINDINGS: Among all the synthesized indole-triazoles, compounds 1-3, and 9-13, and their precursor molecule 1 were found to be active against AGEs production in in vitro glucose- and methylglyoxal (MGO)-BSA models. Compounds 1-2, and 11-13 were also found to be nontoxic against HEPG2, and THP-1 cells. Our results show that pretreatment of THP-1 monocytes with selected lead compounds 1-2, and 11-13, particularly compounds 12, and 13, reduced glucose- and MGO-derived AGEs-mediated ROS production (P < 0.001), as compared to standards, PDTC, rutin, and quercetin. They also significantly (P < 0.001) suppressed NF-ĸB translocation in THP-1 monocytes. Moreover, compounds 12, and 13 attenuated the AGEs-induced COX-2 protein levels (P < 0.001), and PGE2 production (P < 0.001) in THP-1 monocytes. SIGNIFICANCE: Our data revealed that the indole-triazoles 12, and 13 can significantly attenuate the AGEs-induced proinflammatory COX-2 levels, and associated PGE2 production by suppressing AGE-ROS-NF-Kß nexus in THP-1 monocytes. These compounds can thus serve as leads for further evaluation as treatment to delay early onset of diabetic complications.


Assuntos
Produtos Finais de Glicação Avançada/metabolismo , Indóis/farmacologia , Triazóis/farmacologia , Ciclo-Oxigenase 2/metabolismo , Citocinas/metabolismo , Dinoprostona/metabolismo , Produtos Finais de Glicação Avançada/efeitos dos fármacos , Humanos , Indóis/química , Inflamação/metabolismo , Mediadores da Inflamação/metabolismo , Monócitos/metabolismo , NF-kappa B/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Células THP-1 , Triazóis/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...